Though CSF3R mutations have been observed in other myeloid disorders such as hereditary chronic neutrophilia, severe congenital neutropenia (SCN), and in some myeloid leukemia as well, it was in 2013 that a landmark discovery by Maxson et al. identified the disease defining CSF3R mutations in CNL, thus marking a turning point in the molecular pathogenesis of the disease [6,9]. Here, CSF3R is linked to myeloid leukemia.